{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05028348","nct_id":"NCT05028348","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05028348. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Selinexor will be given as an oral dose:\n\n40 mg (2 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.\n\n* Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.\n* Patients ≤75 years:\n\n  o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.\n* Patients \\> 75 years:\n\n  * Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.","label":"Selinexor, pomalidomide and dexamethasone (SPd)","type":"EXPERIMENTAL"},{"description":"Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.\n\n* Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle.\n* Patients ≤75 years:\n\n  * Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing\n  * Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.\n* Patients \\>75 years:\n\n  * Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing\n  * Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.","label":"Elotuzumab, Pomalidomide and Dexamethasone (EloPd)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Karyopharm Therapeutics Inc"],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":117,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Selinexor","otherNames":["KPT-330"],"type":"DRUG"},{"name":"Elotuzumab","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone Oral","otherNames":[],"type":"DRUG"}],"last_update":"2025-12-04","lead_sponsor":"European Myeloma Network B.V.","official_title":"A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"from randomization to the date of disease progression or death (approximately up to 5 years)"}],"references":[],"start_date":{"date":"2022-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05028348"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05028348"}